Esmeralda Ortiz

Leading the transformation of Grupo Loeffler-Russek (GLR) — a family-owned pharmaceutical group with human and animal health divisions — into a professional, results-driven, and governance-oriented organization. Spearheading strategic, cultural, and operational initiatives to strengthen profitability, transparency, and long-term sustainability. Under my leadership, the company achieved a 64% year-over-year net profit increase in 2024, while improving working capital efficiency and corporate governance practices. • Driving institutionalization across finance, operations, and culture to align with global standards. • Implementing leadership renewal and talent development programs to foster collaboration and accountability. • Enhancing capital structure, inventory management, and cash flow to support growth and resilience. • Promoting innovation through InnoPharma, GLR’s R&D spin-off, while strengthening both human and animal health divisions. My leadership approach integrates People, Profit, and Planet, ensuring sustainable growth and trust-based transformation.

Directed a full business transformation and long-term growth plan through innovation, efficiency, and team alignment. • Delivered EBT growth of +47.4% (2019 vs 2018), +32% (2020 vs 2019), +26% (2021 vs 2020). • Implemented new operating model and organizational redesign. • Led over 200 COVID contingency initiatives, creating new markets and saving costs. • Drove e-commerce sales up 728% YoY, implemented SAP successfully, and boosted salesforce productivity by 120%.

Founded a boutique consultancy specializing in turnarounds, strategic planning, and governance for pharmaceutical companies. • Designed strategic and operating models delivering measurable growth. • Conducted market analysis and ROI frameworks for business optimization. • Supported entry into new markets and government tenders. • Served as Independent Board Member, advising on corporate governance.

Revitalized performance and strengthened governance in a competitive FMCG segment. • Reversed negative sales trends; achieved EBT growth of +127% (2016 vs 2015). • Attained ISO-9001 and Food Safety certifications in record time. • Expanded exports to Central America and the U.S., securing FDA compliance.

Led Biotech, Oncology, and Generics (Sandoz) divisions, managing multidisciplinary teams and national operations. • Delivered continuous growth and improved operating margin by +500% vs. 2012. • Developed and executed strategies for government tenders and hospital market expansion. • Reengineered salesforce and incentive model, improving productivity 47%+ and strengthening brand visibility.

Apr 2011 – Aug 2011 · Jan 2005 – Mar 2007 Directed national sales and P&L for the generics division, leading 340+ people across commercial areas. • Surpassed sales and EBT targets; turned around losses into 30% profit margin over revenue. • Expanded key-account sales +110% and improved salesforce productivity +47%. • Opened new channels (Walmart, drugstores) and launched OTC line exceeding targets.

Launched and consolidated the Generics Business Unit in Mexico, overseeing Sales, Marketing, and P&L. • Achieved +72% sales growth (2009) and +27% (2010), recognized internationally for affiliate turnaround. • Increased fill rate from 17% to 97% within two years through supply-chain optimization. • Designed new portfolio and market strategies for government tenders, growing business 300% YoY.

Responsible for opening the private generics market and building national commercial infrastructure. • Exceeded sales targets +120% monthly average and launched key generics successfully. • Created “Seguro Popular” strategy, expanding public-sector business opportunities.

Oversaw product portfolio, trademarks, and new product launches for national retail market. • Achieved 30% sales contribution from new product line “Chanty WIP” and introduced products into Walmart.

Led OTC and natural-products business operations, including marketing, sales, and trade marketing. • Relaunched Vitacilina, achieving 300% growth in 3 months and sustained 40% annual increase thereafter. • Launched Vitacilina Bebé, reaching 30% market share within six months.

Executive Program focused on strategy, leadership, corporate governance, innovation, and global transformation. Participating in a structured Peer Group with international CEOs and senior executives to foster strategic dialogue, share best practices, and build long-term professional connections.